-
Part 1 | Session 12 Meet the expert: Sex differences in advanced heart failure
-
Part 1 | Session 13 Plenary Session 6: How to manage the obese patient with HF
-
Part 2 | Session 1 Plenary Session 7: New technologies to manage your patients
-
Part 2 | Session 3 Plenary Session 8: New technologies to treat your patients
-
Part 2 | Session 4 Plenary Session 9: Comparing European and US recent guidelines
-
Part 2 | Session 8 Plenary Session 11: Managing the HF patient with valvular heart disease
-
Part 2 | Session 10 Plenary Session 12: Managing the patient with worsening and advanced HF
-
Part 1 | Session 3 Plenary Session 2: Managing your HF patients with comorbidities (part 1)
-
Part 1 | Session 6 Plenary Session 3: Using SGLT2 in your patients: practical considerations
-
Part 1 | Session 8 Plenary Session 4: Managing your HF patients with comorbidities (part 2)
e-SPACE Heart Failure 2022 was the third edition of the annual global online conference on heart failure. Bringing together thought-leaders from across the globe and broadcast over three time-zones – Asia, Europe, and the Americas – e-SPACE Heart Failure 2022 optimised geographical reach whilst delivering both global and regional insight.
Course leadership Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE), Dr Javed Butler (Baylor Scott and White Research Institute, Texas, US), Prof Andrew Coats (University of Warwick, Coventry, UK) and Dr Shelley Zieroth (University of Manitoba, Manitoba, CA) lead an interactive programme of plenary sessions, meet the experts, case discussions and industry sponsored sessions focusing on the patient journey.
For the first time, e-SPACE Heart Failure 2022 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Learning Objectives
- Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
- Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
- Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
- Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
- Translate the findings of recent studies and guidelines into optimal patient management in the regional contexts
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Part 1
Day 1
Part 2
Day 2
Faculty Biographies
Mitja Lainscak
Professor, Division of Cardiology
Prof Mitja Lainscak is a Professor in the Division of Cardiology at University of Ljubljana, Ljubljana, SI. He is also Director of the Slovenian Research Agency.
Ambarish Pandey
Assistant Professor in Internal Medicine
Dr Ambarish Pandey is an Assistant Professor in Internal Medicine at University of Texas Southwestern Medical Center, Texas, US.
He obtained his medical degree from All India Institute of Medical Sciences, India and fellowship at UT Southwestern Medical Center (2014-2018).
Dr Pandey specialises in preventive cardiology and heart failure with preserved ejection fraction.
He is a member of the American Heart Association (AHA), where he serves on several committees, including the Scientific Sessions Planning Committee and the Epidemiology Early Career Committee.
Faiez Zannad
Professor Emeritus; Founder and Chairman of CVCT Société Civile
Prof Faiez Zannad was born in Monastir, Tunisia in 1951 and later moved to pursue his medical education and research in Europe. He trained in cardiology and pharmacology across institutions in France and the United Kingdom, including Nancy, Lyon, and Oxford. Over the course of his career, he has lived and worked primarily in Nancy, France, where he has held clinical, academic, and research leadership roles in cardiovascular medicine and therapeutics.
Academic History
Prof Zannad earned his MD in cardiology from the Faculté de Médecine de Nancy and further trained as a research fellow in clinical pharmacology at the Medical Research Council in Oxford. He later received a PhD in cardiovascular clinical pharmacology from the University of Lyon. During his academic training, he focused on cardiovascular pharmacology, physiology, and therapeutic innovation, laying the foundation for his lifelong work in heart failure and hypertension research.
Following…
Justin Ezekowitz
Dr. Ezekowitz, an accomplished professional in the field of cardiology, serves as the co-director of the Canadian VIGOUR Centre at the University of Alberta. He has spearheaded the establishment of five new heart failure clinics across Alberta to enhance access to specialized services. Furthermore, he plays a pivotal role in co-chairing the heart failure care pathway initiative as part of Alberta Health Services Strategic Clinical Networks.
Dr. Ezekowitz's clinical focus centers on cardiology, with a primary emphasis on heart failure. He practices at the Mazankowski Alberta Heart Institute, where he contributes to the Heart Function Clinic.
In the realm of research, Dr. Ezekowitz dedicates his efforts to acute and chronic heart failure, particularly in individuals with heart "pump" issues or end-stage heart disease. He actively engages in numerous local and international clinical trials aimed at identifying novel treatments and care strategies for heart failure…
Ileana L Piña
Dr Ileana L Pina is Professor at the Department of Medicine (Cardiology) and Professor in the Department of Epidemiology and Population Health at Montefiore Einstein Center for Heart and Vascular Care, US.
Dr Piña has a particular research and clinical interest in rehabilitation of heart disease in patients with heart failure. She completed a NHLBI HF ACTION trial and is in the process of examining recovery after exercise which could be translated to an additional parameter that may better predict prognosis of outcomes. In addition, there was a R21 to NHLBI to examine Vitamin D levels as another predictor from the HF ACTION database.
Dr Ileana L Pina is an Editorial Board member of Cardiac Failure Review.
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an internationally known cardiologist, research methodologist, and senior scientist. She serves as an Associate Professor of Medicine at McMaster University, a Senior Scientist at the Population Health Research Institute, and Director of Implementation Science at the Baim Institute for Clinical Research in Boston.
Academic history
Dr Van Spall completed her BSc and MD at the University of Toronto, followed by residency and fellowship training in internal medicine and…